Medis Research Group has been joined by ONKODATAMED GmbH in a bid to consolidate the group's position as an oncology trial specialist...
Medis Research Group, a strategic alliance of Berlin-based CROs, has been joined by another CRO from the Berlin area, ONKODATAMED GmbH, in a bid to consolidate the group’s position as an oncology trial specialist covering Germany, Austria and Switzerland.
Medis was founded in November 2013, and its two founding members were Allied Clinical Management and ICRC-Weyer. The group was formed in a move to better meet requirements of clinical trial sponsors for "one-stop shop solutions."
Onkodatamed is a specialist provider of remote data capture solutions within a network of dermatologic, urologic and gynecologic oncologists. Through this network, Medis now has access to one of the largest epidemiological and clinical oncology databases in Europe containing information on thousands of patients currently in treatment – a valuable source for retrospective data analysis.
“The group’s clinical research services complement the portfolio of Onkodatamed enabling us to jointly provide a wide range of services for the conduct of entire trial projects and retrospective data analysis. On the other hand, we can contribute to the group with our proven remote data capture software ODM QuaSi as well as our large database of urologic and gynecologic oncology patients,” said Dr. Lutz Reimer, Managing Director of Onkodatamed.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.